Pacific Biosciences of California, Inc. (PACB)

PACB Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	200.52	128.3	130.51	78.89	90.89
Revenue Growth (YoY)	56.29%	-1.69%	65.43%	-13.20%	15.60%
Cost of Revenue	147.74	79.27	71.65	46.33	56.32
Gross Profit	52.78	49.04	58.86	32.57	34.58
Selling, General & Admin	169.82	160.85	124.12	72.8	75.49
Research & Development	187.17	193	112.9	64.15	59.63
Other Operating Expenses	15.2	0	31.13	0	0
Operating Expenses	372.19	353.85	268.15	136.95	135.12
Operating Income	-319.41	-304.82	-209.29	-104.39	-100.55
Interest Expense / Income	14.34	14.69	12.53	0.27	2.61
Other Expense / Income	-15.59	-5.26	53.05	-134.06	-19.02
Pretax Income	-318.16	-314.25	-274.87	29.4	-84.13
Income Tax	-11.42	0	-93.65	0	0
Net Income	-306.74	-314.25	-181.22	29.4	-84.13
Shares Outstanding (Basic)	254	225	204	165	153
Shares Outstanding (Diluted)	254	225	204	175	153
Shares Change	12.95%	10.00%	16.67%	14.71%	12.90%
EPS (Basic)	-1.21	-1.40	-0.89	0.18	-0.55
EPS (Diluted)	-1.21	-1.40	-0.89	0.17	-0.55
Free Cash Flow	-268.02	-279.96	-117.11	18.46	-81.15
Free Cash Flow Per Share	-1.06	-1.25	-0.57	0.11	-0.53
Gross Margin	26.32%	38.22%	45.10%	41.28%	38.04%
Operating Margin	-159.29%	-237.58%	-160.36%	-132.31%	-110.62%
Profit Margin	-152.97%	-244.92%	-138.85%	37.27%	-92.57%
Free Cash Flow Margin	-133.66%	-218.20%	-89.73%	23.40%	-89.28%
EBITDA	-277.28	-282.24	-250.76	38.97	-71.58
EBITDA Margin	-138.28%	-219.98%	-192.13%	49.40%	-78.75%
Depreciation & Amortization	26.53	17.32	11.59	9.3	9.95
EBIT	-303.82	-299.56	-262.34	29.67	-81.52
EBIT Margin	-151.51%	-233.48%	-201.01%	37.61%	-89.69%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).